Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Behavioral Management of Chronic Daily Headache
Todd A. Smitherman, PhD, FAHSUniversity of Mississippi
Scott W. Powers, PhD, ABPP, FAHSUniversity of Cincinnati College of Medicine
Cincinnati Children’s Hospital
Learning Objectives
• By the end of this course attendees will be able to…
• Summarize recent advances in behavioral treatments for CDH. • Select evidence‐based interventions for patients with CM, CM with comorbid insomnia, or MOH.
• Implement (or refer for) cost‐efficient behavioral management strategies in conjunction with pharmacotherapy.
Behavioral Treatment of CDH in Adults:Novel Applications
Todd A. Smitherman, PhD
Associate Professor of PsychologyDirector, Center for Behavioral Medicine
University of Mississippi, Oxford MS
None relevant for commercial interests
Funding:Migraine Research Foundation University of Mississippi
Disclosures for Dr. Smitherman
Novel applications: Adapted delivery formats Treating comorbidities to reduce headache Interventions targeting disability (vs
headache reduction)
Behavioral Treatment of CDH in Adults
Cost-effective vs even inexpensive preventive medications
Adapted Delivery Formats
Schafer et al., 2011
38% of migraineurs sleep <6 hours/night vs 10% of general population
Take twice as long to fall asleep
Majority of headache clinic patients have insomnia 68-84% of patients with CM have insomnia Often on a daily basis
Insomnia as an Exemplar Comorbidity
Calhoun et al., 2006; Kelman & Rains, 2005Maizels & Burchette, 2004; Sancisi et al., 2010
American College of Physicians’ Guideline
“ACP recommends that all adult patients receive CBT for insomnia (CBT-I) as the initial treatment for
chronic insomnia”
Qaseem et al, 2016
Treating Comorbid Insomnia Improves CM
Smitherman et al. (2016), follow-up to Calhoun (2007) 31 adults with CM and insomnia ( M = 21 days/month) 3-session CBTi vs sham Daily headache diaries plus actigraphy MOH excluded (vs overused meds discontinued)
Treating Comorbid Insomnia Improves CMI At follow-up odds of headache were 60% less for BT group 48.9% frequency reduction from baseline vs 25% for control
PSQI changes: r = .54 (p =.002) w/ HA probability and r = .46 (p = .018) with HIT-6 changes
Smitherman et al., 2016
Case-Based Application: Assessment Diagnostic Criteria:
Insufficient sleep despite opportunity: <6 hours/night or ≥30 mins to fall/stay asleep
Daytime impairment
REST mnemonic Restorative nature of sleep Excessive daytime sleepiness or fatigue Presence of habitual Snoring Total sleep time
PSQIAmerican Academy of Sleep Medicine; Rains & Poceta, 2006
Case-Based Application: Self-Monitoring
Case-Based Application: Management Stimulus control: Help patient re-associate bed with sleep
Eliminate naps (except those required for migraine relief)
Get out of bed if you can’t sleep within 20-30 mins Use bed only for sleep Keep consistent bedtime and wake time
Case-Based Application: Management Sleep restriction:
Limit time in bed to time spent sleeping
Use daily sleep diaries: calculate average total sleep time and time in bed Sleep efficiency: Total sleep time / Time in bed
Prescribe new bed schedule = avg sleep time + 30 min Increase 20-30min as sleep efficiency reaches 85%
Cautions: Do not restrict anyone to< 5 hours Do not use with bipolar patients (PMR instead)
One’s responses to pain are as important as pain itself
Focus on building “psychological flexibility”: Acceptance, valued action
Target disability more than pain
Acceptance and Commitment Therapy For CDH
145 total RCTs across various conditions Grade A evidence for chronic pain Promising results from 2 headache trials
CTTH/CM: Mo’tamedi et al., 2012 Migraine w/ MDD: Dindo et al., 2012, 2014) Case-based application: post-traumatic headache
Psychological flexibility accounts for 20% of variance in MIDAS scores after controlling for gender and headache severity
ACT Efficacy and Processes
Foote et al., 2016; McCracken & Vowles, 2014; Veehof et al., 2011
Acknowledgments
Migraine Research Foundation
Drs. Brooke Walters, Carrie Ambrose, Rachel Davis
Drs. Jeanetta Rains, Tim Houle, Don Penzien
Dr. Malcolm Roland
QUESTIONS? [email protected]
CCRF Endowed ChairProfessor of Pediatrics and Psychology, University of Cincinnati College of MedicineDirector of Clinical and Translational Research, Cincinnati Children’s Research Foundation
Co-Director, Headache Center, Cincinnati Children’s HospitalDivision of Behavioral Medicine and Clinical Psychology
Funding: NIH:NINDS/NICHD Grants: R01NS050536; U01NS076788; U01NS077108;Migraine Research Foundation; Society of Developmental and Behavioral Pediatrics;Cincinnati Children’s Research Foundation
Disclosures for Dr. PowersFunding:
• NIH:NINDS/NICHD Grants: R01NS050536; U01NS076788; U01NS077108;
• Migraine Research Foundation; • Society of Developmental and Behavioral Pediatrics;• Cincinnati Children’s Research Foundation
• Headache Management Principles
• Biofeedback‐Assisted Relaxation Training
• Activity Pacing
• Recognizing Negative Thoughts and Using Calming Statements
• Problem‐Solving Skills
• Parent Coaching & Reinforcement of Coping
• Medical & Psychosocial Assessment and Diagnosis
• Headache Diary (28 days)
• Randomization
• Treatment Phase (Total of 20 weeks)
• Weekly for 8 weeks• Monthly for 3 months
• Follow‐Up Phase (Total of 12 months)
• Every 3 months
(N=64) (N=71)
Age: 14.4 ± 1.9 14.4 ± 2.1
Gender: 79.7% female 79% female
HA Days: 21.4 ± 5.4 21.2 ± 5.1
Disability 67.3 ± 29.8 69.2 ± 33.8(PedMIDAS): (Severe Grade) (Severe Grade)
• Avg. Tolerated Dose of Amitriptyline = 1.01 ± 0.02 mg/kg/day
• No Serious Adverse Events (Related & Unexpected)
• Total # of Adverse Events = 199 (Context: Total of 2,160 visits)
• Treatment Credibility and Integrity (Both arms had high levels of credibility to participants and parents; CBT & ATT delivered by same therapists who adhered to Tx manuals demonstrating measured integrity – AHS Behavioral Trial Guidelines)
≥ 50% Reduction in Headache Days
At 20 weeks:
ATT+A = 36% of participants
(PedMIDAS < 20)
At 20 weeks:
ATT+A = 56% of participants
At 12 month F/Up for CBT+A Participants:
What are the recent findings from the Cognitive Behavioral Therapy + Amitriptyline Trial?
Trajectory of Improvement in Children and Adolescents with Chronic Migraine: Results from the Cognitive Behavioral Therapy and Amitriptyline TrialJohn W. Kroner, MS1; James Peugh, PhD1,4; Susmita M. Kashikar‐Zuck, PhD1,4; Susan L. LeCates, MSN2,3;
Janelle R. Allen, MS1,3; Shalonda K. Slater, PhD1,3,4; Marium Zafar, PsyD1; Marielle A. Kabbouche, MD, FAHS2,3,4; Hope L. O’Brien, MD, FAHS2,3,4; Chad E. Shenk, PhD1,4; Ashley M. Kroon Van Diest, PhD1; Andrew D. Hershey, MD, PhD, FAHS 2,3,4, Scott W. Powers, PhD, ABPP, FAHS1,3,4
(In press, Journal of Pain)
Month 1 Month 2 Month 3 Month 4 Month 5
HE+ACBT+A
Pro
portion
010
%20
%30
%40
%50
%60
%70
%80
%90
%10
0%
Proportion of patients with 50% or greater reduction in headache days for each month of the 5-month trial
A significantly higher proportion of the CBT+A group had a ≥50% reduction in headache days for months 2 through 5 (Month 2: CBT+A 36%, HE+A 17% p=0.0117; Month 3: CBT+A 48%, HE+A 30% p=0.0245; Month 4: CBT+A 64%, HE+A 41% p=0.0070; Month 5: CBT+A 69%, HE+A 45% p=0.0.0056).
Published online 10/27/2016
What are the implications of the CHAMPTrial and CBT+A Trial for clinical care now?
In pediatric headache clinic next week
• Expect and measure for effect in first 8 weeks
• Take a team approach and use your skills to increase expectation of improvement
If preventive medication, once a day dosing, low dose to prevent side effects. Optimally, combine with CBT.